Ann Lab Med.  2024 Jan;44(1):1-2. 10.3343/alm.2024.44.1.1.

Challenges of Carbapenem-resistant Pseudomonas aeruginosa in Infection Control and Antibiotic Management

• Kim YJ
• Huh HJ
• Sung H

• KMID: 2550209
• DOI: http://doi.org/10.3343/alm.2024.44.1.1

Keyword

Antimicrobial susceptibility; Carbapenem resistance; Pseudomonas aeruginosa; Risk factors; Urinary tract infections

Reference

1. Hansen GT. 2021; Continuous evolution: perspective on the epidemiology of carbapenemase resistance among Enterobacterales and other gram-negative bacteria. Infect Dis Ther. 10:75–92. DOI: 10.1007/s40121-020-00395-2. PMID: 33492641. PMCID: PMC7954928.

2. Liu C, Yoon EJ, Kim D, Shin JH, Shin JH, Shin KS, et al. 2019; Antimicrobial resistance in South Korea: a report from the Korean global antimicrobial resistance surveillance system (Kor-GLASS) for 2017. J Infect Chemother. 25:845–59. DOI: 10.1016/j.jiac.2019.06.010. PMID: 31311694.

3. Korea Centers for Disease Control and Prevention. Kor-GLASS antimicrobial resistance rate. https://www.kdca.go.kr/nohas/en/statistics/selectARStatisticsMainTab.do?systemName=Kor_GLASS. Updated on Dec 2022.

4. Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, et al. 2023; Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. Lancet Microbe. 4:e159–70. DOI: 10.1016/S2666-5247(22)00329-9. PMID: 36774938.

5. Lee HJ, Lee DG. 2022; Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria. Korean J Intern Med. 37:271–80. DOI: 10.3904/kjim.2021.527. PMID: 35272440. PMCID: PMC8925957.

6. Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y, et al. 2022; Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 60:106633. DOI: 10.1016/j.ijantimicag.2022.106633. PMID: 35787918.

7. Mojica MF, Rossi MA, Vila AJ, Bonomo RA. 2022; The urgent need for metallo-beta-lactamase inhibitors: an unattended global threat. Lancet Infect Dis. 22:e28–34. DOI: 10.1016/S1473-3099(20)30868-9. PMID: 34246322.

8. Choi YJ, Kim YA, Junglim K, Jeong SH, Shin JH, Shin KS, et al. 2023; Emergence of NDM-1-producing Pseudomonas aeruginosa sequence type 773 clone: shift of carbapenemase molecular epidemiology and spread of 16S rRNA methylase genes in Korea. Ann Lab Med. 43:196–9. DOI: 10.3343/alm.2023.43.2.196. PMID: 36281514. PMCID: PMC9618910.

9. Jeong S, Lee N, Park MJ, Jeon K, Kim HS, Kim HS, et al. 2022; Genotypic distribution and antimicrobial susceptibilities of carbapenemase-producing Enterobacteriaceae isolated from rectal and clinical samples in Korean university hospitals between 2016 and 2019. Ann Lab Med. 42:36–46. DOI: 10.3343/alm.2022.42.1.36. PMID: 34374347. PMCID: PMC8368229.

10. Jeong S, Jeon K, Lee N, Park MJ, Song W. 2024; Changing genotypic distribution, antimicrobial susceptibilities, and risk factors of urinary tract infection caused by carbapenemase-producing Pseudomonas aeruginosa. Ann Lab Med. 44:38–46. DOI: 10.3343/alm.2024.44.1.38. PMID: 37665284.

11. Zhang P, Shi Q, Hu H, Hong B, Wu X, Du X, et al. 2020; Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect. 26:124.e1–4. DOI: 10.1016/j.cmi.2019.08.020. PMID: 31494252.

12. Fatemi Y, Bergl PA. 2022; Diagnostic stewardship: appropriate testing and judicious treatments. Crit Care Clin. 38:69–87. DOI: 10.1016/j.ccc.2021.09.002. PMID: 34794632.

13. Zakhour J, Haddad SF, Kerbage A, Wertheim H, Tattevin P, Voss A, et al. 2023; Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance. Int J Antimicrob Agents. 62:106816. DOI: 10.1016/j.ijantimicag.2023.106816. PMID: 37061101.